CClinicalTrials.gg
Active, not recruitingNCT04467489Updated Aug 11, 2025

Biomarkers of CASH

An observational study in Cerebral Cavernous Malformation, Cavernous Angioma and Hemorrhagic Microangiopathy, sponsored by University of Chicago. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by University of Chicago · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,040
Ages
18 Years and older
Sex
All
01

Study summary

The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.

Read the detailed description

Cerebral cavernous angioma (CA) is a capillary microangiopathy affecting more than a million Americans, predisposing them to a premature risk of brain hemorrhage. Fewer than 200,000 cases who have suffered a recent symptomatic hemorrhage (SH) are most likely to re-bleed again with serious clinical sequelae, and are the primary focus of therapeutic development. Genetic mechanisms of CA have been extensively studied, and consequent signaling aberrations in the neurovascular unit. These include proliferative dysangiogenesis, blood-brain barrier hyperpermeability, inflammation and immune mediated processes, anticoagulant vascular domain, and gut microbiome-driven mechanisms. Plasma levels of molecules reflecting these mechanisms and measures of vascular permeability and hemorrhage leak on magnetic resonance imaging (MRI) have been correlated with CA hemorrhage in pilot studies. It would be desirable to optimize these biomarkers to accurately diagnose CASH, to prognosticate the risk of future SH, and to monitor cases after a bleed and in response to therapy. This would influence clinical management, and select higher risk cases for clinical trials. Additional candidate biomarkers are emerging from ongoing mechanistic and differential transcriptome studies, which would be expected to further enhance the sensitivity and specificity of diagnosis and prediction of CASH. Weighed combinations of levels of plasma proteins and characteristic micro-ribonucleic acids (miRNA) may further strengthen biomarker associations. Plasma biomarkers may reflect (and potentially replace) more cumbersome and expensive imaging biomarkers for monitoring CA hemorrhage. We here assemble CA researchers and propose to deploy advanced statistical and computational biology approaches for the integration of novel candidate biomarkers. In Specific Aim 1 we assess these biomarkers in a large CA cohort to discover the best plasma biomarkers and validate them in sex, age and relevant clinical subgroups. In Specific Aim 2 we compare changes in MRI measures of vascular permeability and hemorrhage with plasma biomarkers over time. In Specific Aim 3 we query the biomarkers in non-CA subjects, to identify potential confounders in the clinical context. This project integrates analytic and computational biology expertise to develop blood tests for better CASH diagnosis and prognosis. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease with a relevant context of use. This approach is applicable to other neurological diseases with similar pathobiologic features.

02

Conditions studied

  • Cerebral Cavernous Malformation
  • Cavernous Angioma
  • Hemorrhagic Microangiopathy

Keywords

  • plasma biomarker
  • imaging biomarker
  • machine learning
03

In context

Lead sponsor

University of Chicago is the lead sponsor of 907 studies on the registry; 182 are open to participants now.

Of its 99 completed or terminated interventional studies of FDA-regulated products, 68 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We propose to recruit human subjects at three sites, with the project approved and coordinated by the University of Chicago Medicine (UCM) central institutional review board (IRB) and endorsed by respective IRBs at the other two enrolling sites. The study involves no more than minimal risks, discussed herein. The enrolling sites include UCM where the project will be led and where the data coordinating center (DCC) is located and all plasma biomarker assays and statistical analyses are planned, the University of California at San Francisco (UCSF), and Mayo Clinic, Rochester, MN (Mayo). UCSF and Mayo are participants in imaging biomarker validations in longitudinal follow-up of cavernous angioma with symptomatic hemorrhage (CASH) subjects in the TR Project. We project enrolling 1,040 cases during 4 years to address hypotheses in 3 Specific Aims (40 cases enrolled in Specific Aim 2 are also included among the 800 subjects addressing hypotheses of Specific Aim 1).

Eligibility criteria

Aim 1 and 2:

Inclusion Criteria:

  1. Clinical diagnosis of CA
  2. age 18 or older
  3. solitary or multiple
  4. familial or sporadic
  5. with or without prior symptoms

Exclusion Criteria:

  1. Prior excision of a solitary CA lesion
  2. prior stereotactic radiosurgery or any brain irradiation
  3. spinal cavernoma without brain lesion
  4. other brain pathology unrelated to CA (demyelinating disease, brain tumor)
  5. seizures or stroke unrelated to CA in the prior year
  6. current pregnancy or within 6 months postpartum
  7. reluctance to undergo venipuncture or donate blood specimen, or be called for clinical follow-up for up to one year
  8. homeless or incarcerated persons, or other reason a subject will be unable/unlikely to be reached for follow-up

Aim 3:

Inclusion Criteria:

  1. \< 30 years of age
  2. one or more seizures (with or without medical therapy) in the prior year

OR

  1. > 50 years of age
  2. having received an MRI of the brain with SWI (susceptibility weighted imaging) sequences for any indication in the year prior to enrollment
  3. No HMA on brain MRI SWI sequences

OR

  1. > 50 years of age
  2. having received an MRI of the brain with SWI sequences for any indication in the year prior to enrollment
  3. Two or more microbleeds on SWI brain MRI sequences, adjudicated by neuroradiologist

Exclusion Criteria:

  1. concurrent brain disease or structural brain pathology
  2. medical illness requiring hospitalization or surgery, seizure or stroke in the prior 12 months
  3. active use of prescription medications in the prior 12 months
  4. current pregnancy or within 6 months postpartum
  5. reluctance to undergo venipuncture or donate blood specimen

OR

  1. concurrent brain disease or structural brain pathology
  2. medical illness requiring hospitalization or surgery, or stroke in the prior 12 months other than seizure disorder
  3. active use of prescription medications in the prior 12 months except anticonvulsants
  4. current pregnancy or within 6 months postpartum
  5. reluctance to undergo venipuncture or donate blood specimen

OR

  1. concurrent brain disease or structural brain pathology
  2. medical illness requiring hospitalization or surgery within the prior year
  3. any history of stroke or epileptic seizure within the prior year
  4. current pregnancy or within 6 months postpartum
  5. reluctance to undergo venipuncture or donate blood specimen

OR

  1. concurrent brain disease or structural brain pathology
  2. medical illness requiring hospitalization or surgery within the prior year
  3. any history of stroke or epileptic seizure within the prior year
  4. current pregnancy or within 6 months postpartum
  5. reluctance to undergo venipuncture or donate blood specimen
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,040 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • CA (non-CASH)

    Cavernous Angioma (CA) without symptomatic hemorrhage cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting

    Other: observational

  • CA (CASH)

    Cavernous Angioma (CA) with Symptomatic Hemorrhage (SH) cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting

    Other: observational

  • Young with seizure

    Young (\<30 years old) healthy control cohorts with seizures in the prior year

    Other: observational

  • Young without seizure

    Young (\<30 years old) healthy control cohorts without seizures in the prior year

    Other: observational

  • Older with HMA

    Older (\>50 years old) with hemorrhagic microangiopathy (HMA)

    Other: observational

  • Older without HMA

    Older (\>50 years old) without hemorrhagic microangiopathy (HMA)

    Other: observational

Interventions

  • Otherobservational

    There is no intervention for any group in this observational study.

06

What researchers measure

Primary outcomes

  1. Circulating Diagnostic and Prognostic Biomarkers of CASH

    To test whether individual and combined levels of candidate plasma proteins and miRNAs can be associated with diagnosis of CASH (cross sectional) and can predict/prognosticate future SH (longitudinal) in CAs

    Time frame: 5 years

Secondary outcomes

  1. Correlation of Imaging and Plasma Biomarkers of CASH

    To assess whether changes in QSM (quantitative susceptibility mapping) and DCEQP (dynamic contrast enhanced quantitative permeability) used as monitoring biomarkers after a SH, are reflected by changes in plasma biomarkers and miRNAs

    Time frame: 5 years

  2. Confounders of CASH Biomarkers

    To assess the plasma biomarkers in non-CA young and older subjects, with and without seizures and hemorrhagic microangiopathy on MRI, to clarify potential confounders in the context of clinical use, and to motivate novel hypotheses for broader applications

    Time frame: 5 years

07

Study locations

4 sites
  • Barrow Neurological Institute at St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • University of California, San Francisco
    San Francisco, California 94117, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

References and documents

Publications

  • Girard R, Li Y, Stadnik A, Shenkar R, Hobson N, Romanos S, Srinath A, Moore T, Lightle R, Shkoukani A, Akers A, Carroll T, Christoforidis GA, Koenig JI, Lee C, Piedad K, Greenberg SM, Kim H, Flemming KD, Ji Y, Awad IA. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 Feb 16;88(3):686-697. doi: 10.1093/neuros/nyaa478. PubMed 33469662 ↗

Individual participant data

Plan to share: Yes — Within the first year, we will publish the protocol paper. At the end of the 5 year study, we will publish the data dictionary along with study findings. The expression profile data will be made publicly available no later than the date of initial publication or six months after the receipt of the final sequencing data, whichever comes first.

Supporting information: Study protocol, Sap

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04467489
Lead sponsor
University of Chicago
Collaborators
Mayo Clinic, University of California, San Francisco, National Institute of Neurological Disorders and Stroke (NINDS), Barrow Neurological Institute
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
May 22, 2020
Primary completion
Apr 30, 2025
Completion
Jun 30, 2026 (estimated)
Last update
Aug 11, 2025

Study contacts

Issam Awad, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion